Clinical Trial

Ticagrelor Versus Cilostazol in Ischemic Stroke

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate and moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.
Trial Details
NCT Number NCT06561867
Lead Sponsor Kafrelsheikh University
Conditions Ischemic Stroke
Enrollment 900 participants
Start Date 2024-08-30
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-20 (estimated)
Updated on ClinicalTrials.gov 2024-08-20